

# Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

New England Journal of Medicine

374, 1647-1660

DOI: [10.1056/nejmoa1502924](https://doi.org/10.1056/nejmoa1502924)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease. Cellular Physiology and Biochemistry, 2015, 37, 1641-1658.	1.6	8
2	First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). Open Forum Infectious Diseases, 2015, 2, ofv082.	0.9	58
3	One Health, Vaccines and Ebola: The Opportunities for Shared Benefits. Journal of Agricultural and Environmental Ethics, 2015, 28, 1011-1032.	1.7	27
4	Filoviruses: One of These Things is (not) Like the Other. Viruses, 2015, 7, 5172-5190.	3.3	27
5	Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material. Viruses, 2015, 7, 6739-6754.	3.3	29
6	Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathogens, 2015, 11, e1005276.	4.7	138
7	The crux and crust of ebolavirus: Analysis of genome sequences and glycoprotein gene. Biochemical and Biophysical Research Communications, 2015, 463, 756-761.	2.1	3
8	New options to fight Ebola. Nature Reviews Drug Discovery, 2015, 14, 385-385.	46.4	1
9	Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses. Journal of Infectious Diseases, 2015, 212, S414-S424.	4.0	49
10	Ebola vaccine R&D: Filling the knowledge gaps. Science Translational Medicine, 2015, 7, 317ps24.	12.4	41
11	Ebola: Europe-Africa research collaborations. Lancet Infectious Diseases, The, 2015, 15, 1258-1259.	9.1	10
12	The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infectious Diseases, The, 2015, 15, 1156-1166.	9.1	251
13	Editorial Commentary: All's (Almost) Quiet on the Western Front: Will We Be Ready for the Next War?. Clinical Infectious Diseases, 2015, 61, 503-505.	5.8	1
14	Against the clock towards new Ebola virus therapies. Virus Research, 2015, 209, 4-10.	2.2	14
15	Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection: Table 1.. Journal of Infectious Diseases, 2015, 212, S91-S97.	4.0	116
16	New options to fight Ebola. Nature Reviews Microbiology, 2015, 13, 327-327.	28.6	1
17	Clinical development of Ebola vaccines. Therapeutic Advances in Vaccines, 2015, 3, 125-138.	2.7	65
18	Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort. Lancet Infectious Diseases, The, 2015, 15, 1117-1119.	9.1	9

#	ARTICLE	IF	CITATIONS
19	Ebola virus vaccines“preparing for the unexpected. <i>Science</i> , 2015, 349, 693-694.	12.6	4
20	VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. <i>Science</i> , 2015, 349, 739-742.	12.6	213
21	Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	3
22	West Africa 2013: Re-examining Ebola. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	16
23	The Importance of Mammalogy, Infectious Disease Research, and Biosafety in the Field. , 2016, 2016, 3.		1
24	How are Vaccines Assessed in Clinical Trials?. , 2016, , 97-119.		0
25	Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. <i>PLoS ONE</i> , 2016, 11, e0162446.	2.5	26
26	Vaccines for Emerging Viral Diseases. , 2016, , 543-560.		1
27	A Genomic Landscape of Haplotype Diversity and Signatures of Phylogeographic Distribution in Zaire Ebolavirus during the 2014 EVD Epidemic. , 2016, , .		0
28	Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2016, 34, 6597-6609.	3.8	53
29	B and T Cell Epitope-Based Peptides Predicted from Evolutionarily Conserved and Whole Protein Sequences of Ebola Virus as Vaccine Targets. <i>Scandinavian Journal of Immunology</i> , 2016, 83, 321-337.	2.7	21
30	Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3429-3435.	2.2	41
31	Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. <i>Scientific Reports</i> , 2016, 6, 27944.	3.3	72
32	Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays. <i>Scientific Reports</i> , 2016, 6, 23803.	3.3	20
33	Ebola virus vaccines “reality or fiction?. <i>Expert Review of Vaccines</i> , 2016, 15, 1421-1430.	4.4	29
34	Ebola virus encodes a miR-155 analog to regulate importin- $\beta 5$ expression. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 3733-3744.	5.4	29
35	Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus. <i>Clinical Infectious Diseases</i> , 2016, 63, 376-379.	5.8	26
36	Ebola virus disease candidate vaccines under evaluation in clinical trials. <i>Expert Review of Vaccines</i> , 2016, 15, 1101-1112.	4.4	50

#	ARTICLE	IF	CITATIONS
37	On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa. <i>Current Opinion in Virology</i> , 2016, 17, 138-144.	5.4	48
38	Ebola vaccines - Where are we?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2700-2703.	3.3	3
39	Patch Models of EVD Transmission Dynamics. , 2016, , 147-167.		4
40	Ebola virus disease and critical illness. <i>Critical Care</i> , 2016, 20, 217.	5.8	97
41	Monoclonal antibodies for the treatment of Ebola virus disease. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1325-1335.	4.1	34
43	Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. <i>Journal of Infectious Diseases</i> , 2016, 214, S360-S366.	4.0	62
44	After Ebola in West Africa - Unpredictable Risks, Preventable Epidemics. <i>New England Journal of Medicine</i> , 2016, 375, 587-596.	27.0	216
45	Molecular mechanisms of Ebola pathogenesis. <i>Journal of Leukocyte Biology</i> , 2016, 100, 889-904.	3.3	31
46	Yellow fever in Africa. <i>BMJ, The</i> , 2016, 354, i3764.	6.0	5
47	Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 21674.	3.3	54
48	Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16021.	4.4	63
49	Ebola virus vaccines: Where do we stand?. <i>Clinical Immunology</i> , 2016, 173, 44-49.	3.2	32
50	Comprehensive characterization of cellular immune responses following Ebola virus infection. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw508.	4.0	38
51	Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	1
52	Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. <i>Scientific Reports</i> , 2016, 6, 19193.	3.3	27
53	Statistics and logistics: Design of Ebola vaccine trials in West Africa. <i>Clinical Trials</i> , 2016, 13, 87-91.	1.6	11
54	Ethical Rationale for the Ebola - Ring Vaccination - Trial Design. <i>American Journal of Public Health</i> , 2016, 106, 432-435.	2.7	37
55	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	27.0	295

#	ARTICLE	IF	CITATIONS
56	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. <i>Clinical Trials</i> , 2016, 13, 49-56.	1.6	63
58	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 31-42.	9.1	187
59	Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity. <i>EBioMedicine</i> , 2016, 3, 67-78.	6.1	49
60	Ebola virus disease: emergence, outbreak and future directions. <i>British Medical Bulletin</i> , 2016, 117, 95-106.	6.9	21
61	Stability of a Vesicular Stomatitis Virusâ€“Vectored Ebola Vaccine. <i>Journal of Infectious Diseases</i> , 2016, 213, 930-933.	4.0	21
62	Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 1124-1133.	4.0	24
63	Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. <i>Nature Immunology</i> , 2016, 17, 204-213.	14.5	148
64	Ebola vaccines: we have options. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 267-268.	9.1	3
65	Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus. <i>Medical Microbiology and Immunology</i> , 2016, 205, 173-183.	4.8	32
66	The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e1-e9.	9.1	18
67	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 330-341.	27.0	314
69	An update on the 2014 Ebola outbreak in Western Africa. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 6-10.	0.8	15
70	Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 613-620.	3.3	92
71	Ebola and Marburg: Out of Africa. , 2017, , 131-154.		0
72	Implications of Toll-like receptors in Ebola infection. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 415-425.	3.4	20
73	Ebola virus disease and pregnancy: A review of the current knowledge of Ebola virus pathogenesis, maternal, and neonatal outcomes. <i>Birth Defects Research</i> , 2017, 109, 353-362.	1.5	61
74	A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160295.	4.0	33
75	A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	48

#	ARTICLE	IF	CITATIONS
76	Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection. <i>Scientific Reports</i> , 2017, 7, 919.	3.3	31
77	Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout. <i>Vaccine</i> , 2017, 35, 5481-5486.	3.8	8
78	Neuropsychological long-term sequelae of Ebola virus disease survivors – A systematic review. <i>Travel Medicine and Infectious Disease</i> , 2017, 18, 18-23.	3.0	49
79	Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. <i>EBioMedicine</i> , 2017, 19, 107-118.	6.1	64
80	Insights from clinical research completed during the west Africa Ebola virus disease epidemic. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e280-e292.	9.1	69
81	Advances in Ebola virus vaccination. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 787-788.	9.1	2
82	Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. <i>Cmaj</i> , 2017, 189, E819-E827.	2.0	67
83	Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology. <i>Vaccine</i> , 2017, 35, 4461-4464.	3.8	28
84	Safety and immunogenicity of the rVSVΔGP-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 854-866.	9.1	105
85	Clinical Management of Patients with Ebola Virus Disease in High-Resource Settings. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 115-137.	1.1	3
86	Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2017, 215, 1789-1798.	4.0	65
87	Closer than ever to an Ebola virus vaccine. <i>Expert Review of Vaccines</i> , 2017, 16, 401-402.	4.4	5
88	Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2017, 389, 621-628.	13.7	168
89	Safety and immunogenicity of a recombinant adenovirus vector-based Ebola vaccine. <i>Lancet</i> , The, 2017, 389, 578-580.	13.7	3
90	Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). <i>Lancet</i> , The, 2017, 389, 505-518.	13.7	837
91	Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. <i>The Lancet Global Health</i> , 2017, 5, e324-e334.	6.3	85
92	A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 266-270.	3.3	51
93	Interest in an Ebola vaccine among a U.S. national sample during the height of the 2014–2016 Ebola outbreak in West Africa. <i>Vaccine</i> , 2017, 35, 508-512.	3.8	16

#	ARTICLE	IF	CITATIONS
94	Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane. Expert Review of Vaccines, 2017, 16, 1241-1252.	4.4	43
95	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Human Vaccines and Immunotherapeutics, 2017, 13, 3020-3032.	3.3	67
96	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. New England Journal of Medicine, 2017, 377, 1438-1447.	27.0	199
97	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 <sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNA. Vaccine Journal, 2017, 24, .	3.1	33
98	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Reports, 2017, 20, 2251-2261.	6.4	107
99	Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Human Vaccines and Immunotherapeutics, 2017, 13, 2078-2085.	3.3	28
100	A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice. Antiviral Research, 2017, 145, 54-59.	4.1	10
102	Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. Drugs, 2017, 77, 1935-1966.	10.9	156
103	Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine, 2017, 35, 4465-4469.	3.8	44
104	Ebola Virus Disease in Humans: Pathophysiology and Immunity. Current Topics in Microbiology and Immunology, 2017, 411, 141-169.	1.1	31
105	Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic. BMC Medical Ethics, 2017, 18, 43.	2.4	50
106	Ebola vaccines in clinical trial: The promising candidates. Human Vaccines and Immunotherapeutics, 2017, 13, 153-168.	3.3	48
107	Toward an Effective Ebola Virus Vaccine. Annual Review of Medicine, 2017, 68, 371-386.	12.2	29
108	The predictor of mortality outcome in adult patients with Ebola virus disease during the 2014–2015 outbreak in Guinea. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 689-695.	2.9	7
109	Ebola virus disease: An update on current prevention and management strategies. Journal of Clinical Virology, 2017, 86, 5-13.	3.1	25
110	Marburg- and Ebolaviruses. Current Topics in Microbiology and Immunology, 2017, , .	1.1	4
111	Therapeutics Against Filovirus Infection. Current Topics in Microbiology and Immunology, 2017, 411, 263-290.	1.1	3
112	4. Ein Rückblick: Kreative Personen als Urheber bedeutender medizinischer Innovationen. , 2017, , 81-190.		0

#	ARTICLE	IF	CITATIONS
113	A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus. <i>Frontiers in Immunology</i> , 2017, 8, 252.	4.8	23
115	Fighting Ebola: A Window for Vaccine Re-evaluation?. <i>PLoS Pathogens</i> , 2017, 13, e1006037.	4.7	13
116	Safety and immunogenicity of rVSV <sup>Δ</sup> G-ZEBOV-GP Ebola vaccine in adults and children in Lambaré, Gabon: A phase I randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002402.	8.4	57
117	Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. <i>Reproductive Health</i> , 2017, 14, 172.	3.1	69
118	Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. <i>AIDS Research and Therapy</i> , 2017, 14, 55.	1.7	20
119	Replication-Competent Viral Vectors for Vaccine Delivery. , 2017, , 25-63.		1
120	Lessons learned from Ebola Vaccine R&D during a public health emergency. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2114-2115.	3.3	16
121	Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins. <i>Journal of Virology</i> , 2018, 92, .	3.4	36
122	Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 738-748.	9.1	62
123	Immune barriers of Ebola virus infection. <i>Current Opinion in Virology</i> , 2018, 28, 152-160.	5.4	25
124	Post-exposure treatments for Ebola and Marburg virus infections. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 413-434.	46.4	104
125	A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. <i>Scientific Reports</i> , 2018, 8, 864.	3.3	43
126	The current landscape of nucleic acid tests for filovirus detection. <i>Journal of Clinical Virology</i> , 2018, 103, 27-36.	3.1	13
127	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. <i>Microbiology Spectrum</i> , 2018, 6, .	3.0	6
128	Forecasting Ebola with a regression transmission model. <i>Epidemics</i> , 2018, 22, 50-55.	3.0	24
129	Musculoskeletal manifestations of Ebola virus. <i>Rheumatology</i> , 2018, 57, 28-31.	1.9	8
130	Ebola virus disease: an update on post-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e192.	9.1	112
131	Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. <i>Journal of Virology</i> , 2018, 92, .	3.4	34



#	ARTICLE	IF	CITATIONS
132	From bench to almost bedside: the long road to a licensed Ebola virus vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 159-173.	3.1	35
133	Vaccines against Ebola virus. <i>Vaccine</i> , 2018, 36, 5454-5459.	3.8	43
134	Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice. <i>Human Gene Therapy</i> , 2018, 29, 87-95.	2.7	7
135	Serological Evidence for the Circulation of Ebolaviruses in Pigs From Sierra Leone. <i>Journal of Infectious Diseases</i> , 2018, 218, S305-S311.	4.0	20
136	Development of Ebola Vaccine Candidate by in Silico from Glikoprotein (GP) Gene of Ebola Zaire Virus. <i>Journal of Physics: Conference Series</i> , 2018, 1090, 012081.	0.4	0
137	Pre-clinical development of a vaccine against Lassa fever. <i>Canada Communicable Disease Report</i> , 2018, 44, 139-147.	1.3	3
138	Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?. <i>Expert Review of Vaccines</i> , 2018, 17, 1105-1110.	4.4	14
139	Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer. <i>Human Gene Therapy Clinical Development</i> , 2018, 29, 226-232.	3.1	11
140	Health Conditions in an Adult Population in Sierra Leone: Data Reported From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE). <i>Journal of Infectious Diseases</i> , 2018, 217, S75-S80.	4.0	1
141	Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola. <i>Journal of Infectious Diseases</i> , 2018, 217, S33-S39.	4.0	5
142	Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. <i>PLoS ONE</i> , 2018, 13, e0202753.	2.5	39
143	Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV. <i>Vaccine</i> , 2018, 36, 7083-7094.	3.8	6
144	Unprecedented pace and partnerships: the story of and lessons learned from one Ebola vaccine program. <i>Expert Review of Vaccines</i> , 2018, 17, 913-923.	4.4	9
145	Generation of therapeutic antisera for emerging viral infections. <i>Npj Vaccines</i> , 2018, 3, 42.	6.0	10
146	Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques. <i>PLoS ONE</i> , 2018, 13, e0202997.	2.5	11
147	Intranasal vaccination with ebola virus GP amino acids 258-601 protects mice against lethal challenge. <i>Vaccine</i> , 2018, 36, 6053-6060.	3.8	8
148	Rapid Establishment of a Cold Chain Capacity of -60°C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone. <i>Journal of Infectious Diseases</i> , 2018, 217, S48-S55.	4.0	34
149	Ebola: Lessons on Vaccine Development. <i>Annual Review of Microbiology</i> , 2018, 72, 423-446.	7.3	51

#	ARTICLE	IF	CITATIONS
150	Comment: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE). <i>Journal of Infectious Diseases</i> , 2018, 217, S1-S5.	4.0	3
151	The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVΔ <sup>GP</sup> -ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak. <i>Journal of Infectious Diseases</i> , 2018, 217, S6-S15.	4.0	66
152	The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2107-2113.	3.3	107
153	Monitoring Serious Adverse Events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola. <i>Journal of Infectious Diseases</i> , 2018, 217, S24-S32.	4.0	5
154	A comparative computational genomics of Ebola Virus Disease strains: In-silico Insight for Ebola control. <i>Informatics in Medicine Unlocked</i> , 2018, 12, 106-119.	3.4	15
155	Modern Production Strategies in the Vaccine Industry. , 2018, , 877-898.		0
156	A VSV-based Zika virus vaccine protects mice from lethal challenge. <i>Scientific Reports</i> , 2018, 8, 11043.	3.3	63
157	Correlates of vaccine-induced protective immunity against Ebola virus disease. <i>Seminars in Immunology</i> , 2018, 39, 65-72.	5.6	44
158	A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus. <i>Journal of Infectious Diseases</i> , 2018, 218, 1883-1889.	4.0	14
159	Prevention of Ebola virus disease through vaccination: where we are in 2018. <i>Lancet, The</i> , 2018, 392, 787-790.	13.7	103
160	Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. <i>International Journal of Infectious Diseases</i> , 2018, 74, 83-96.	3.3	21
161	Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. <i>Frontiers in Immunology</i> , 2018, 9, 1803.	4.8	65
162	New Vaccine Technologies to Combat Outbreak Situations. <i>Frontiers in Immunology</i> , 2018, 9, 1963.	4.8	437
163	DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost. <i>Scientific Reports</i> , 2018, 8, 12459.	3.3	21
164	Development of Gene-Based Vectors for Immunization. , 2018, , 1305-1319.e8.		3
165	Ebola Vaccines. , 2018, , 276-287.e5.		0
166	Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2269-2285.	3.3	58
167	Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔ <sup>GP</sup> -ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2019, 220, 1127-1135.	4.0	42

#	ARTICLE	IF	CITATIONS
168	Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach. <i>Microorganisms</i> , 2019, 7, 402.	3.6	16
169	Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2359-2377.	3.3	31
170	Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. <i>PLoS Pathogens</i> , 2019, 15, e1008061.	4.7	35
171	Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge. <i>EBioMedicine</i> , 2019, 49, 223-231.	6.1	34
172	Multilamellar Vaccine Particle Elicits Potent Immune Activation with Protein Antigens and Protects Mice against Ebola Virus Infection. <i>ACS Nano</i> , 2019, 13, 11087-11096.	14.6	33
173	Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells. <i>Vaccine</i> , 2019, 37, 6624-6632.	3.8	25
174	Ebola Virus: Pathogenesis and Countermeasure Development. <i>Annual Review of Virology</i> , 2019, 6, 435-458.	6.7	50
175	Vesiculopolins, a New Class of Anti-Vesiculoviral Compounds, Inhibit Transcription Initiation of Vesiculoviruses. <i>Viruses</i> , 2019, 11, 856.	3.3	7
176	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. <i>Journal of Infectious Diseases</i> , 2019, 219, 1187-1197.	4.0	59
177	Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads. <i>ACS Omega</i> , 2019, 4, 2353-2361.	3.5	49
178	Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. <i>Npj Vaccines</i> , 2019, 4, 5.	6.0	45
179	Biomechanical characterization of TIM protein-mediated Ebola virus-host cell adhesion. <i>Scientific Reports</i> , 2019, 9, 267.	3.3	29
180	Association of Ebola Virus Infection With Hearing Loss in Regions Where Ebola Virus Infection Is Endemic. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 669.	2.2	2
181	Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. <i>PLoS ONE</i> , 2019, 14, e0215457.	2.5	35
182	rVSV <sup>Δ</sup> G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine: X</i> , 2019, 1, 100009.	2.1	61
183	Intradermal SynCon <sup>®</sup> Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. <i>Journal of Infectious Diseases</i> , 2019, 220, 400-410.	4.0	91
184	A Vesicular Stomatitis Virus-Based Vaccine Carrying Zika Virus Capsid Protein Protects Mice from Viral Infection. <i>Virologica Sinica</i> , 2019, 34, 106-110.	3.0	8
185	Pseudovirus rVSV <sup>Δ</sup> G-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice. <i>Cell Reports</i> , 2019, 26, 1718-1726.e4.	6.4	29

#	ARTICLE	IF	CITATIONS
186	Ebola virus disease. <i>Lancet</i> , The, 2019, 393, 936-948.	13.7	305
187	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. , 2019, , 263-278.		0
188	Introductory Chapter: Human Adenoviruses. , 2019, , .		1
189	Ebola Virus Disease. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 953-976.	5.1	36
190	Ebola vaccine trials: progress in vaccine safety and immunogenicity. <i>Expert Review of Vaccines</i> , 2019, 18, 1229-1242.	4.4	61
191	Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebola virus. <i>Cell Reports</i> , 2019, 29, 2537-2545.e3.	6.4	7
192	A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice. <i>Viruses</i> , 2019, 11, 1149.	3.3	11
193	Current Ebola Virus Vaccine Progress. <i>BioDrugs</i> , 2019, 33, 9-14.	4.6	32
194	Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 414-425.	3.3	17
195	Detectable Vesicular Stomatitis Virus (VSV)â€“Specific Humoral and Cellular Immune Responses Following VSVâ€“Ebola Virus Vaccination in Humans. <i>Journal of Infectious Diseases</i> , 2019, 219, 556-561.	4.0	29
196	Arthritis and arthralgia as an adverse event following immunization: A systematic literature review. <i>Vaccine</i> , 2019, 37, 372-383.	3.8	8
197	A Modified Case Definition to Facilitate Essential Hospital Care During Ebola Outbreaks. <i>Clinical Infectious Diseases</i> , 2019, 68, 1763-1768.	5.8	6
198	Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea. <i>Vaccine</i> , 2019, 37, 7171-7177.	3.8	22
199	Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs. <i>Vaccine</i> , 2019, 37, 7178-7182.	3.8	7
200	Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency. <i>Vaccine</i> , 2019, 37, 7443-7450.	3.8	22
201	Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2020, 222, 572-582.	4.0	38
202	Serological evidence of exposure to ebolaviruses in domestic pigs from Guinea. <i>Transboundary and Emerging Diseases</i> , 2020, 67, 724-732.	3.0	9
203	Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report. <i>Clinical Infectious Diseases</i> , 2020, 71, 2872-2879.	5.8	17

#	ARTICLE	IF	CITATIONS
204	Ebola virus disease: An emerging and re-emerging viral threat. <i>Journal of Autoimmunity</i> , 2020, 106, 102375.	6.5	79
205	Missed vaccinations and critical care admission: all you may wish to know or rediscoverâ€”a narrative review. <i>Intensive Care Medicine</i> , 2020, 46, 202-214.	8.2	7
206	Challenges in the Development of a Vaccine Against COVID-19. <i>Engineering</i> , 2020, 6, 1067-1069.	6.7	0
207	Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. <i>Pathogens</i> , 2020, 9, 850.	2.8	16
208	To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. <i>Microorganisms</i> , 2020, 8, 1473.	3.6	12
209	New viral vectors for infectious diseases and cancer. <i>Seminars in Immunology</i> , 2020, 50, 101430.	5.6	55
210	Pandemic vaccine trials: expedite, but donâ€™t rush. <i>Research Ethics</i> , 2020, 16, 1-12.	1.7	3
211	Rhabdoviruses as vectors for vaccines and therapeutics. <i>Current Opinion in Virology</i> , 2020, 44, 169-182.	5.4	17
212	Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. <i>Scientific Reports</i> , 2020, 10, 14289.	3.3	12
213	Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins. <i>Viruses</i> , 2020, 12, 915.	3.3	13
214	Ervebo (Ebola Zaire Vaccine, Live/rVSVÎ”G-ZEBOV-GP): The First Licensed Vaccine for the Prevention of Ebola Virus Disease. <i>Journal of Pharmacy Technology</i> , 2020, 36, 243-250.	1.0	12
215	Environmental Risk Assessment for rVSVÎ”G-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease. <i>Vaccines</i> , 2020, 8, 779.	4.4	10
216	Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures. <i>Vaccine</i> , 2020, 38, 7949-7955.	3.8	8
217	Epitopes of Naturally Acquired and Vaccineâ€”Induced Antiâ€”Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution. <i>Biotechnology Journal</i> , 2020, 15, 2000069.	3.5	9
218	Humoral and cellular immune response induced by rVSVÎ”G-ZEBOV-GP vaccine among frontline workers during the 2013â€”2016 West Africa Ebola outbreak in Guinea. <i>Vaccine</i> , 2020, 38, 4877-4884.	3.8	14
219	A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector. <i>Vaccines</i> , 2020, 8, 241.	4.4	12
220	Ebola Virus Neutralizing Antibodies in Dogs from Sierra Leone, 2017. <i>Emerging Infectious Diseases</i> , 2020, 26, 760-763.	4.3	1
221	Pregnancy Outcomes among Women Receiving rVSVÎ”G-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola. <i>Emerging Infectious Diseases</i> , 2020, 26, 541-548.	4.3	26

#	ARTICLE	IF	CITATIONS
222	Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. <i>Transfusion</i> , 2020, 60, 1024-1031.	1.6	32
223	Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 636-637.	9.1	1
224	The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms. <i>Expert Review of Vaccines</i> , 2020, 19, 267-277.	4.4	17
225	Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebola virus vaccination. <i>Npj Vaccines</i> , 2020, 5, 32.	6.0	18
226	Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus “Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis. <i>Vaccine</i> , 2020, 38, 4885-4891.	3.8	12
227	A tool with many applications: vesicular stomatitis virus in research and medicine. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1187-1201.	3.1	35
228	A Perspective on Emerging Therapeutic Interventions for COVID-19. <i>Frontiers in Public Health</i> , 2020, 8, 281.	2.7	49
229	Safety, immunogenicity and risk“benefit analysis of rVSV-ŒG-ZEBOV-GP (V920) Ebola vaccine in Phase I“III clinical trials across regions. <i>Future Microbiology</i> , 2020, 15, 85-106.	2.0	23
230	A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	17
231	Safety and immunogenicity of a highly attenuated rSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 455-466.	9.1	22
232	Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X“ hydro fixed-bed. <i>Journal of Biotechnology</i> , 2020, 310, 32-39.	3.8	24
233	Safety and immunogenicity of vesicular stomatitis virus-based vaccines for Ebola virus disease. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 388-389.	9.1	3
234	Development of an antibody cocktail for treatment of Sudan virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3768-3778.	7.1	23
235	COVID-19 vaccines: breaking record times to first-in-human trials. <i>Npj Vaccines</i> , 2020, 5, 34.	6.0	92
236	The epidemiology, diagnosis and treatment of COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105955.	2.5	672
237	An effective CTL peptide vaccine for Ebola Zaire Based on Survivors“™ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design. <i>Vaccine</i> , 2020, 38, 4464-4475.	3.8	47
238	Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 719-730.	9.1	47
239	Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers. <i>Clinical Infectious Diseases</i> , 2021, 72, 2035-2041.	5.8	15

#	ARTICLE	IF	CITATIONS
240	Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 507-516.	9.1	26
241	Severe fever with thrombocytopenia syndrome virus: a highly lethal bunyavirus. <i>Critical Reviews in Microbiology</i> , 2021, 47, 112-125.	6.1	63
242	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 168-189.	13.7	62
243	Is there a role for childhood vaccination against COVID-19?. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 9-16.	2.6	38
244	Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine. <i>Vaccines</i> , 2021, 9, 67.	4.4	10
245	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-12.	61.1	37
246	Development of sustainable research excellence with a global perspective on infectious diseases: Centre de Recherches Médicales de Lambaré (CERMEL), Gabon. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 500-508.	1.9	14
247	No Evidence of rVSV-Ebola Virus Vaccine Replication or Dissemination in the Sand Fly <i>Phlebotomus papatasi</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	1.4	1
248	Development of Pandemic Vaccines: ERVEBO Case Study. <i>Vaccines</i> , 2021, 9, 190.	4.4	39
249	Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection. <i>Frontiers in Immunology</i> , 2020, 11, 599568.	4.8	16
250	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. <i>Journal of Virology</i> , 2021, 95, .	3.4	6
251	Under consent: participation of people with HIV in an Ebola vaccine trial in Canada. <i>BMC Medical Ethics</i> , 2021, 22, 42.	2.4	4
252	Viral Pseudotyping: A Novel Tool to Study Emerging and Transboundary Viruses. , 2021, , 17-23.		0
253	Effects of Gamma Irradiation of Human Serum Samples from rVSV-G-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1751-1754.	1.4	2
254	Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein. <i>Journal of Infectious Diseases</i> , 2021, 224, 1907-1915.	4.0	7
255	Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	4
256	Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3771-3783.	3.3	3
257	Vaccine Development Throughout History. <i>Cureus</i> , 2021, 13, e16635.	0.5	19



#	ARTICLE	IF	CITATIONS
258	Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1. <i>Journal of Virology</i> , 2021, 95, e0236820.	3.4	12
259	Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector. <i>Pathogens</i> , 2021, 10, 1092.	2.8	29
260	Cancer Clinical Trials in Africa—An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials. <i>JCO Global Oncology</i> , 2021, 7, 1358-1363.	1.8	11
261	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 817-838.	46.4	577
262	Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. <i>Pathogens</i> , 2021, 10, 1201.	2.8	9
263	High dose of vesicular stomatitis virus-vectorized Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. <i>Emerging Microbes and Infections</i> , 2021, 10, 651-663.	6.5	5
264	Integrin Alpha E (CD103) Limits Virus-Induced IFN-I Production in Conventional Dendritic Cells. <i>Frontiers in Immunology</i> , 2020, 11, 607889.	4.8	1
265	Accelerating Vaccine Development During the 2013–2016 West African Ebola Virus Disease Outbreak. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 229-261.	1.1	14
266	Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 994-1002.	3.3	7
267	Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs. <i>Journal of General Virology</i> , 2018, 99, 866-879.	2.9	5
268	Comparative evaluation of pathogenicity of three isolates of vesicular stomatitis virus (Indiana) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 34	2.9	6
270	Lassa virus diversity and feasibility for universal prophylactic vaccine. <i>F1000Research</i> , 2019, 8, 134.	1.6	29
271	In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease. <i>F1000Research</i> , 2015, 4, 104.	1.6	23
272	Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. <i>Wellcome Open Research</i> , 2018, 3, 39.	1.8	46
273	Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. <i>Wellcome Open Research</i> , 2018, 3, 39.	1.8	48
274	Developing Global Norms for Sharing Data and Results during Public Health Emergencies. <i>PLoS Medicine</i> , 2016, 13, e1001935.	8.4	122
275	Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004802.	3.0	8
276	Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey. <i>PLoS ONE</i> , 2017, 12, e0173148.	2.5	7



#	ARTICLE	IF	CITATIONS
277	Method feasibility for cross-species testing, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for non-human primate serum samples. PLoS ONE, 2020, 15, e0241016.	2.5	7
278	Implementing an Ebola Vaccine Study in Sierra Leone. MMWR Supplements, 2016, 65, 98-106.	35.0	60
279	A Mathematical model of Ebola Virus Disease: Using Sensitivity Analysis to Determine Effective Intervention Targets. , 2016, , .		2
280	A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?. Electronic Journal of General Medicine, 2020, 17, em251.	0.7	12
281	Effect of Gamma Irradiation on the Antibody Response Measured in Human Serum from Subjects Vaccinated with Recombinant Vesicular Stomatitis Virus Zaire Ebola Virus Envelope Glycoprotein Vaccine. American Journal of Tropical Medicine and Hygiene, 2019, 101, 207-213.	1.4	12
282	VSV-EBOV Induces Temporal and Dose-Dependent Transcriptional Responses in Non-human Primates. Frontiers in Virology, 2021, 1, .	1.4	0
283	Imaging of High and Low Resolution Ebola Envelope GP Structures Compositod with in silico Models of Difficult-to-Resolve Sections. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2015, 09, .	0.1	0
284	Ebola Fever and Advances in the Antiviral Therapies. Journal of Human Virology & Retrovirology, 2015, 2, .	0.2	0
285	Filoviruses. , 0, , 981-1007.		1
286	Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. , 0, , 39-52.		0
287	New viral outbreaks: time for rheumatologists to get involved?. Rheumatology, 2017, 56, 2046-2047.	1.9	1
288	Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Ebola virus disease. EFSA Journal, 2017, 15, e04890.	1.8	1
289	Introduction to the volume. , 2017, , 1-18.		0
290	Ebola-Impfstoff-Entwicklung: Im Krisenfall schnell, aber mit hohem Sicherheitsanspruch. Deutsches A&#x0308;rzteblatt International, 0, , .	0.9	0
292	Ebola Virus Disease Musculoskeletal Manifestations. , 2019, , 143-146.		0
293	Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. Current Opinion in Virology, 2021, 51, 179-189.	5.4	7
295	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recommendations and Reports, 2021, 70, 1-12.	61.1	0
296	Updates on Treatment of Ebola Virus Disease. The Malaysian Journal of Medical Sciences, 2015, 22, 54-57.	0.5	0

#	ARTICLE	IF	CITATIONS
297	Animal Models of Ebolavirus Infection. <i>Comparative Medicine</i> , 2017, 67, 253-262.	1.0	33
298	The Pathogenesis and Treatment of COVID-19: A System Review. <i>Biomedical and Environmental Sciences</i> , 2021, 34, 50-60.	0.2	4
299	Viral-vectored vaccines against SARS-CoV-2. , 2022, , 115-127.		1
300	Vaccine Development in the Midst of Ebolavirus Disease Outbreaks. <i>RSC Drug Discovery Series</i> , 2021, , 121-165.	0.3	0
301	Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies. <i>RSC Drug Discovery Series</i> , 2021, , 91-120.	0.3	0
302	Filoviruses: modern solutions to life-threatening infections. , 2022, , 369-394.		0
304	Immunogenicity of rVSV-G-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	8
305	Transcriptomic signatures induced by the Ebola virus vaccine rVSV-G-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. <i>Lancet Microbe</i> , The, 2022, 3, e113-e123.	7.3	6
306	Isothermal nucleic acid amplification technology for rapid detection of virus. <i>Critical Reviews in Biotechnology</i> , 2023, 43, 415-432.	9.0	13
307	Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein. <i>Vaccines</i> , 2022, 10, 533.	4.4	5
308	mRNA vaccines for COVID-19 and diverse diseases. <i>Journal of Controlled Release</i> , 2022, 345, 314-333.	9.9	50
309	Ebolavirus: Infection, Vaccination and Control. <i>Molecular Genetics, Microbiology and Virology</i> , 2021, 36, S55-S64.	0.3	0
310	The Development of mRNA Vaccines for Infectious Diseases: Recent Updates. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5271-5285.	2.7	16
311	Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis. <i>Frontiers in Immunology</i> , 2022, 13, 857481.	4.8	9
313	Effect of Recombinant Vesicular Stomatitis Virus Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo. <i>Emerging Infectious Diseases</i> , 2022, 28, .	4.3	4
314	A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010433.	3.0	20
315	Overview of recent advances in Vero cells genomic characterization and engineering for high-throughput vaccine manufacturing. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.5	5
316	Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10

#	ARTICLE	IF	CITATIONS
317	Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. <i>Nature Communications</i> , 2022, 13, .	12.8	6
318	Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccinationâ€”Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay. <i>Vaccines</i> , 2022, 10, 1211.	4.4	5
319	From functional genomics of vero cells to CRISPRâ€“based genomic deletion for improved viral production rates. <i>Biotechnology and Bioengineering</i> , 0, , .	3.3	1
320	CDCâ€™s COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions. <i>Emerging Infectious Diseases</i> , 2022, 28, .	4.3	3
322	Lessons Learned from the Development and Roll-Out of the rVSVâ€™G-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines. <i>Vaccines</i> , 2022, 10, 1446.	4.4	2
323	Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials. <i>Vaccines</i> , 2022, 10, 1582.	4.4	3
324	Immunogenicity of rVSVâ€™G-ZEBOV-GP Ebola vaccine (ERVEBOâ€™) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. <i>Vaccine</i> , 2022, 40, 6599-6606.	3.8	10
326	Recombinant vesicular stomatitis virusâ€“vectored vaccine induces long-lasting immunity against Nipah virus disease. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	7
328	Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge. <i>Npj Vaccines</i> , 2023, 8, .	6.0	2
329	Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	23
330	Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates. <i>Cell Reports</i> , 2023, 42, 112402.	6.4	6
331	Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine. <i>EBioMedicine</i> , 2023, 89, 104463.	6.1	10
332	Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina. <i>Frontiers in Virology</i> , 0, 3, .	1.4	2
333	Replicating-Competent VSV-Vectored Pseudotyped Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 329-348.	1.6	2
334	Lessons from Pasteur may help prevent the deadly relapse of Ebola in patients: Using contingency vaccination to avoid Ebola relapse in immune-privileged organs. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
335	Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV. <i>Vaccines</i> , 2023, 11, 977.	4.4	1
336	A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus. <i>Journal of Infectious Diseases</i> , 2023, 228, S660-S670.	4.0	6
337	Advances in mRNA vaccines for viral diseases. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	2

#	ARTICLE	IF	CITATIONS
338	YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge. <i>Npj Vaccines</i> , 2023, 8, .	6.0	0
339	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
340	Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSVMT) in golden syrian hamster. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 4856-4874.	12.0	0
341	Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability. <i>Clinical Microbiology and Infection</i> , 2023, 29, 1587-1594.	6.0	0
342	Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates. <i>Science Advances</i> , 2023, 9, .	10.3	1
344	Baseline gene signatures of reactogenicity to Ebola vaccination: a machine learning approach across multiple cohorts. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
345	Vaccines to prevent Ebola virus disease: current challenges and perspectives. <i>Voprosy Virusologii</i> , 2023, 68, 372-384.	0.7	0
346	Immunogenicity and vaccine shedding after 1 or 2 doses of rVSV <sup>Δ</sup> G-ZEBOV-GP Ebola vaccine (ERVEBO <sup>®</sup> ): Results from a phase 2, randomized, placebo-controlled trial in children and adults. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	1
347	Presence and Persistence of Andes Virus RNA in Human Semen. <i>Viruses</i> , 2023, 15, 2266.	3.3	1
348	Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSV <sup>Δ</sup> G-ZEBOV-GP. <i>IScience</i> , 2023, 26, 108574.	4.1	1
349	Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial. <i>Wellcome Open Research</i> , 0, 8, 182.	1.8	1
350	Immunogenicity and safety of ebolavirus vaccines in healthy adults: a systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Vaccines</i> , 2024, 23, 148-159.	4.4	0
351	Monoclonal antibody applications in travel medicine. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2024, 10, .	2.2	0
352	Refined innate plasma signature after rVSV <sup>Δ</sup> G-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
353	Design of universal Ebola virus vaccine candidates via immunofocusing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2024, 121, .	7.1	0
355	A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease. <i>Cell Reports Medicine</i> , 2024, 5, 101467.	6.5	0